Erste Asset Management GmbH Cuts Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Erste Asset Management GmbH reduced its stake in Regeneron Pharmaceuticals by 8.3%, selling 3,349 shares, bringing its total holdings to 37,033 shares valued at approximately $23.57 million.
• Regeneron reported earnings per share of $12.89 in its last quarter, significantly exceeding the consensus estimate of $8.43, with quarter revenues of $3.68 billion.
• Regeneron announced a quarterly dividend of $0.88, with a dividend yield of 0.6%, to be paid on September 3rd to stockholders of record on August 18th.

Erste Asset Management GmbH reduced its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 8.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 37,033 shares of the biopharmaceutical company's stock after selling 3,349 shares during the quarter. Erste Asset Management GmbH's holdings in Regeneron Pharmaceuticals were worth $23,565,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Marietta Wealth Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 30.2% during the first quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock valued at $6,836,000 after purchasing an additional 2,501 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 89,825.0% during the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after purchasing an additional 814,713 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Regeneron Pharmaceuticals by 3.9% during the first quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock valued at $16,255,000 after purchasing an additional 955 shares in the last quarter. KBC Group NV lifted its holdings in shares of Regeneron Pharmaceuticals by 9.4% during the first quarter. KBC Group NV now owns 149,440 shares of the biopharmaceutical company's stock valued at $94,779,000 after purchasing an additional 12,793 shares in the last quarter. Finally, Lmcg Investments LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 231.3% during the first quarter. Lmcg Investments LLC now owns 14,481 shares of the biopharmaceutical company's stock valued at $9,184,000 after purchasing an additional 10,110 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN traded down $8.68 during trading on Friday, hitting $589.48. The company had a trading volume of 1,438,624 shares, compared to its average volume of 992,485. The stock has a 50 day simple moving average of $550.48 and a 200 day simple moving average of $592.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,211.20. The firm has a market capitalization of $62.48 billion, a P/E ratio of 14.86, a price-to-earnings-growth ratio of 1.99 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The firm had revenue of $3,675,600 billion for the quarter, compared to the consensus estimate of $3.30 billion. During the same quarter last year, the company earned $11.56 earnings per share. The business's revenue for the quarter was up 3.6% compared to the same quarter last year. As a group, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be given a dividend of $0.88 per share. The ex-dividend date is Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.87%.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Canaccord Genuity Group reissued a "buy" rating and issued a $850.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, July 23rd. Guggenheim increased their target price on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a "buy" rating in a report on Friday, August 1st. JPMorgan Chase & Co. lowered their target price on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a report on Monday, June 9th. Redburn Atlantic raised Regeneron Pharmaceuticals to a "strong-buy" rating in a report on Thursday, August 14th. Finally, Citigroup reissued a "buy" rating and issued a $650.00 target price on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $829.65.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.